Pre-IND Briefing Book (OBX-319)
📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Pre-IND Briefing Book (OBX-319)
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Pre-IND Briefing Book (OBX-319)
Document ID: MTG-PreIND
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): FDA meetings
Pre-IND Meeting Briefing Book — OBX-319
Briefing package for the Pre-IND interaction on OBX-319 in Systemic Lupus Erythematosus (moderate-to-severe active): development rationale, the nonclinical package supporting first-in-human dosing, the proposed clinical starting dose and Phase 1 design, and the specific questions for the Agency. FDA meeting guidance.
Comments (0)
No comments yet. Be the first to say something!